Clinical trials: FAPI
Tumor, Solid, Positron-Emission Tomography
Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer
To evaluate the normal physiological distribution of positron nuclide labeled DOTA-FAPI PET/CT in human body and its diagnostic efficiency for colorectal cancers
- Conditions
- Tumor, Solid, Positron-Emission Tomography, Colorectal Cancer
- Trial name
- NCT04750772
- Testing
- 18F-FDG and 68Ga-DOTA-FAPI04 PET/CT, 18F-FDG and 18F-DOTA-FAPI04 PET/CT
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Peking University Cancer Hospital & Institute
Myositis, Idiopathic Inflammatory Myopathies
Characterizing Myositis With 68Ga-FAPI PET/CT
To evaluate the potential usefulness of 68Ga-FAPI PET/CT for the diagnosis and evaluation of systemic involvement in idiopathic inflammatory myopathies (IIM)/myositis, and compared the results with those of 18F-FDG PET/CT.
- Trial name
- NCT05952531
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 50 people
- Sponsor
- The First Affiliated Hospital of Xiamen University
Vulvar Squamous Cell Carcinoma
In Vitro Study of [18F]F-FAPI-74 Feasibility in Vulvar Cancer
This study aims to investigate the expression of FAP by phosphor imaging in invasive vulvar squamous cell carcinoma specimens. This in vitro study will include all consecutive tumour specimens stored both in optimal cutting…
- Trial name
- FAPI_VULVA_1 (NCT06911801)
- Where
- Italy
- Volunteers
- 90 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Thyroid Cancer
177Lu-CTR-FAPI for the Treatment of Thyroid Cancer
This is a multi-center, open-label, single-arm, dose-escalation phase I study, aiming to evaluate the safety and efficacy of 177Lu-CTR-FAPI (covalent targeted radioligand-fibroblast activation protein inhibitor), a novel…
- Trial name
- NCT07438847
- Testing
- 177Lu-CTR-FAPI therapy
- Where
- 2 sites in China
- Volunteers
- 12 people
- Sponsor
- SHAOYAN LIU
Fibroblast Activation Protein Inhibitor, PET/CT
68Ga-FAPI PET/CT in Malignant Tumors
Fibroblast-activation protein (FAP) is a type Ⅱ transmembrane serine protease and is overexpressed in cancer-associated fibroblasts (CAFs). CAFs are the predominant component in the stroma of epithelial neoplasms.
- Conditions
- Fibroblast Activation Protein Inhibitor, PET/CT, Malignant Neoplasm
- Trial name
- NCT05034146
- Testing
- 68Ga-FAPI, PET/CT
- Where
- China
- Volunteers
- 500 people, healthy volunteers welcome
- Sponsor
- Zhongnan Hospital
Malignant Neoplasm
FAPI-PET for Tumor Detection
This is a prospective observational trial investigating correlation with histopathology, positive predictive value, detection rate, reproducibility and impact on clinical management of 68-Ga-FAPI PET/CT or PET/MRI in patients…
- Trial name
- NCT04571086
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- University Hospital, Essen
Cancer
Application of FDG Combined With FAPI PET Dual Imaging in the Diagnosis and Staging of Oropharyngeal and Laryngeal Cancer
According to statistics, in 2020, new head and neck malignancies in the world accounted for 4.9% (931931 cases) of malignant tumors in the whole body, and the new death cases were 467125, accounting for 4.7% of malignant tumors…
- Trial name
- NCT06304155
- Testing
- Diagnostic efficacy,SUV
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
IBD (Inflammatory Bowel Disease), Crohn Disease (CD)
FAPi-PET Imaging of in Vivo Fibrosis in Inflammatory Bowel Disease Patients
Our main objective is to evaluate the feasibility of 68Ga-FAPi PET/CT in detecting intestinal fibrosis in patients with IBD. To this end, we will determine 68Ga-FAPi uptake in IBD in relation to cellular FAP expression in…
- Conditions
- IBD (Inflammatory Bowel Disease), Crohn Disease (CD), Ulcerative Colitis (UC)
- Trial name
- PIMAFI (NCT06604260)
- Testing
- 68Ga-FAPi-46
- Where
- Netherlands
- Volunteers
- 20 people
- Sponsor
- Dalia Lartey
Malignant Neoplasm
FAPI PET/CT Prospective Interobserver Agreement
The aim of the present study is to evaluate the interobserver agreement for FAPI PET/CT interpretations of representative cancer types and compare findings among readers with different levels of experience.
- Trial name
- AGREE-FAPI (NCT04990882)
- Testing
- Interpretation of FAPI-PET/CT scans
- Where
- Germany
- Volunteers
- 15 people
- Sponsor
- University Hospital, Essen
Colon Cancer
Colon Cancer Diagnosis With FAPI-PET Imaging
Whole body CT is the primary imaging method in staging and follow-up of colon cancer. Conventional PET-CT with 18F-labeled fluorodeoxyglucose (18F-FDG) has its limitations and has a secondary role in colon cancer protocols.
- Trial name
- NCT07272772
- Testing
- PET/CT ([F-18]FAPI-74)
- Where
- Finland
- Volunteers
- 100 people
- Sponsor
- Turku University Hospital
Tumour
To Compare the Clinical Application of 18F-LNC1007 Injection PET/CT and 18F-FDG PET/CT
To evaluate the safety of 18F-LNC1007 injection in the diagnosis of suspected tumor, initial stage, or recurrence monitoring; to explore the biological distribution of 18F-LNC1007 injection in patients; To compare the diagnostic…
- Trial name
- 18F-LNC1007 (NCT06205888)
- Testing
- 18F-LNC1007（18F-FAPI-RGD） PET/CT和18F-FDG PET/CT
- Sponsor
- Jinling Hospital, China
HCM - Hypertrophic Cardiomyopathy
Effect of Henagliflozin on Myocardial Fibrosis in Non-Obstructive HCM: A Randomized, Double-Blind, Placebo-Controlled Trial Using 68Ga/18F-FAPI PET/CMR
his is a single-center, randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effect of Henagliflozin (an SGLT2 inhibitor) on myocardial fibrosis burden in patients with non-obstructive hypertrophic…
- Trial name
- NCT07294495
- Testing
- Henagliflozin (SGLT2 Inhibitor)
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Shanghai East Hospital
Gastrointestinal Cancer
Study of 18F-FAPI Applied to Gastrointestinal Cancer
Comparison of tumor volume, number, and SUVmax of different primary foci (gastric, duodenal, and colon cancer), lymph node metastases (neck and supraclavicular, mediastinal, abdominal, and pelvic), and distant metastases (brain…
- Trial name
- NCT05788874
- Testing
- 18F-FAPI and 18F-FDG PET/CT
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- First Affiliated Hospital Xi'an Jiaotong University
Lung Cancer (Diagnosis)
18F-FAPI PET in Lung Cancer
This study aims to evaluate the diagnostic efficacy and prognostic value of 18F-FAPI PET/CT in lung cancer.
- Trial name
- NCT07370805
- Testing
- 18F-FAPI PET
- Where
- China
- Volunteers
- 120 people
- Sponsor
- First Affiliated Hospital of Zhejiang University
Peritoneal Metastasis, Gastric Cancer
The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.
This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.
- Trial name
- NCT06597526
- Where
- China
- Volunteers
- 30 people
- Sponsor
- Ruijin Hospital
BREAST CANCER, PET/CT
68Ga FAPI PET/CT Evaluation of Axillary Lymph Node Status After Neoadjuvant Therapy in Patients With Clinical Axillary Lymph Node Positive Breast Cancer
The goal of this observational study is to learn whether 68Ga-FAPI PET/CT may be used as a new effective methods for evaluating axillary lymph node efficacy after neoadjuvant treatment for breast cancer.
- Trial name
- NCT06559371
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Kunwei Shen
Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic
Molecular Imaging of Fibroblast Activation Protein Expression Using Labeled Technetium-99m HYNIC-FAPI
The study should evaluate the biological distribution of 99mTc-HYNIC-FAPI in metastatic cancer patients.
- Conditions
- Lung Cancer (Locally Advanced or Metastatic), Pancreas Cancer, Metastatic, Breast Cancer (Locally Advanced or Metastatic), Colorectal Cancer (Locally Advanced or Metastatic)
- Trial name
- NCT07457541
- Testing
- [99mTc]Tc-HYNIC-FAPI
- Where
- Russia
- Volunteers
- 15 people
- Sponsor
- Tomsk National Research Medical Center of the Russian Academy of Sciences
Prostate Cancer, Prostate Cancer Metastatic
The Diagnostic Value of FAPI PET/CT in Staging of Newly Diagnosed Prostate Cancer
This study aims to investigate the diagnostic value of FAPI PET/CT, relative to standard-of-care imaging using PSMA PET/CT, in staging of newly diagnosed PCa.
- Trial name
- proFAPI (NCT06634173)
- Testing
- FAPI PET/CT
- Volunteers
- 30 people
- Sponsor
- The Netherlands Cancer Institute
SAPHO Syndrome
Characterizing SAPHO With 68Ga-FAPI PET/CT
68Ga-FAPI has been developed as a tumor-targeting agent as fibroblast activation protein is overexpressed in cancer-associated fibroblasts and some inflammation.
- Trial name
- NCT04596462
- Testing
- 68Ga-FAPI
- Where
- China
- Volunteers
- 70 people
- Sponsor
- Peking Union Medical College Hospital
Crohn Disease
18F-FDG and 68Ga-FAPI PET/CT in Crohn's Disease
Intestinal stricture is a complication of Crohn's disease (CD), which is thought to be the result of chronic transmural inflammation combined with a dysregulated wound-healing process.
- Trial name
- NCT04502303
- Testing
- 18F-FDG and 68Ga-FAPI PET/CT
- Volunteers
- 30 people
- Sponsor
- Peking Union Medical College Hospital